# OnCo record invasive-lobular-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/invasive-lobular-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "invasive-lobular-carcinoma" ;
  schema:name "Invasive lobular carcinoma of the breast"@en ;
  schema:alternateName "Invasive lobular carcinoma"@en, "ILC"@en, "Lobular breast cancer"@en, "Invasive lobular breast cancer"@en, "Infiltrating lobular carcinoma"@en, "Pleomorphic lobular carcinoma"@en ;
  schema:description "Invasive lobular carcinoma is the second most common type of breast cancer, about one in seven cases. Its cells have lost the glue protein E-cadherin, so they spread in single files rather than forming a lump, which makes it hard to see on mammograms and to measure. Almost all cases are hormone-receptor positive and are treated like other hormone-driven breast cancer."@en ;
  schema:url <https://onco.cc/cancers/invasive-lobular-carcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Invasive_lobular_carcinoma> ;
  schema:citation <https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/invasive-lobular-breast-cancer>, <https://doi.org/10.1111/his.14091>, <https://doi.org/10.1016/j.cell.2015.09.033>, <https://doi.org/10.3390/healthcare11050746>, <https://doi.org/10.1016/j.amjsurg.2021.05.021>, <https://doi.org/10.1371/journal.pone.0089778>, <https://doi.org/10.2147/bctt.s126341> ;
  onco:tag "subtype-page", "wave4", "breast" ;
  onco:related <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/invasive-breast-carcinoma-no-special-type/>, <https://onco.cc/cancers/lobular-carcinoma-in-situ/>, <https://onco.cc/cancers/tubular-carcinoma-breast/>, <https://onco.cc/cancers/neuroendocrine-neoplasms-breast/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdh1/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/> ;
  onco:terms <https://onco.cc/terms/mastectomy/> ;
  onco:trials <https://onco.cc/trials/nct04252859/> ;
  onco:standardOfCare <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/terms/mastectomy/> .